ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2018

Sep 11, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2018-09-06

Reporting Person: Myszkowski Kenneth Allen (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-06	Common Stock	M	25000	$2.62	Acquired	335815	Direct
2018-09-06	Common Stock	M	20000	$4.75	Acquired	355815	Direct
2018-09-06	Common Stock	S	25000	$18.00	Disposed	330815	Direct
2018-09-06	Common Stock	S	20000	$21.01	Disposed	310815	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-06	Stock Option (right to buy)	$2.62	M	25000	Disposed	2022-09-28	Common Stock (25000)	Direct
2018-09-06	Stock Option (right to buy)	$4.75	M	20000	Disposed	2023-09-21	Common Stock (20000)	Direct

Footnotes

F1: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

F4: Represents first vesting date. Option vests over four years from date of grant.